Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Argus Health
Queensland Health
Colorcon
Harvard Business School
Citi
Healthtrust
Fuji

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

« Back to Dashboard

Clinical Trials for Hydrochlorothiazide; Spironolactone

Trial ID Title Status Sponsor Phase Summary
NCT00007592 Hypertension Screening and Treatment Program Completed VA Office of Research and Development N/A Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00224549 PHARES Study: Management of Resistant Hypertension Completed Assistance Publique - Hôpitaux de Paris Phase 4 The purpose of this study is to assess the efficacy of two different treatment regimens for treating resistant hypertension previously uncontrolled with at least 3 antihypertensive treatments. The study hypothesis is that these two regimens (one based on increasing diuretics and the other based on increasing renin angiotensin system blockage) may not differ in terms of efficacy.
NCT00515021 Diurnal Variation of Plasminogen Activator Inhibitor-1 Unknown status National Center for Research Resources (NCRR) Phase 4 To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma PAI-1 levels more effectively than morning administration.
NCT00515021 Diurnal Variation of Plasminogen Activator Inhibitor-1 Unknown status Vanderbilt University Medical Center Phase 4 To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma PAI-1 levels more effectively than morning administration.
NCT00865124 Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease Completed National Institutes of Health (NIH) N/A Aldosterone is a significant mediator of cardiovascular injury associated with heart failure and the cardiovascular benefits of mineralocorticoid receptor blockade are additive to those of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. This study will test the hypothesis that MR antagonists exert beneficial cardiovascular effects, specifically by decreasing vascular injury and improving vascular function.A randomized, double-blind study will be conducted, in which subjects with Type 2 Diabetes Mellitus will undergo a series of assessments to test heart, blood vessel, and kidney function at baseline, and after 2 and 6 months of treatment with one of the following drugs: 1. spironolactone 2. hydrochlorothiazide plus potassium 3. placebo. In the event of insufficient funds, randomization to the placebo arm will be stopped and primary assessment of outcomes will occur at baseline and after 6 months of treatment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Hydrochlorothiazide; Spironolactone

Condition Name

Condition Name for Hydrochlorothiazide; Spironolactone
Intervention Trials
Hypertension 3
Stroke 1
Patients With Fungic Infections 1
Metabolic Syndrome X 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hydrochlorothiazide; Spironolactone
Intervention Trials
Hypertension 3
Vascular Diseases 1
Diabetes Mellitus, Type 2 1
Diabetes Mellitus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hydrochlorothiazide; Spironolactone

Trials by Country

Trials by Country for Hydrochlorothiazide; Spironolactone
Location Trials
United States 12
France 1
Mexico 1
Puerto Rico 1
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hydrochlorothiazide; Spironolactone
Location Trials
Tennessee 2
Massachusetts 1
Virginia 1
Pennsylvania 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hydrochlorothiazide; Spironolactone

Clinical Trial Phase

Clinical Trial Phase for Hydrochlorothiazide; Spironolactone
Clinical Trial Phase Trials
Phase 4 4
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hydrochlorothiazide; Spironolactone
Clinical Trial Phase Trials
Completed 3
Terminated 1
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hydrochlorothiazide; Spironolactone

Sponsor Name

Sponsor Name for Hydrochlorothiazide; Spironolactone
Sponsor Trials
Brigham and Women's Hospital 1
National Institutes of Health (NIH) 1
Vanderbilt University Medical Center 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hydrochlorothiazide; Spironolactone
Sponsor Trials
Other 5
NIH 2
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson
Express Scripts
Covington
Fuji
US Army
UBS
Fish and Richardson
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.